[go: up one dir, main page]

DK3236972T3 - Antivirale N4-hydroxycytidin-derivativer - Google Patents

Antivirale N4-hydroxycytidin-derivativer Download PDF

Info

Publication number
DK3236972T3
DK3236972T3 DK15874145.4T DK15874145T DK3236972T3 DK 3236972 T3 DK3236972 T3 DK 3236972T3 DK 15874145 T DK15874145 T DK 15874145T DK 3236972 T3 DK3236972 T3 DK 3236972T3
Authority
DK
Denmark
Prior art keywords
hydroxycytidin
derivativer
antivirale
Prior art date
Application number
DK15874145.4T
Other languages
Danish (da)
Inventor
George R Painter
David B Guthrie
Gregory R Bluemling
Michael G Natchus
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56151433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3236972(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Emory filed Critical Univ Emory
Application granted granted Critical
Publication of DK3236972T3 publication Critical patent/DK3236972T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK15874145.4T 2014-12-26 2015-12-16 Antivirale N4-hydroxycytidin-derivativer DK3236972T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462096915P 2014-12-26 2014-12-26
US201562201140P 2015-08-05 2015-08-05
PCT/US2015/066144 WO2016106050A1 (en) 2014-12-26 2015-12-16 N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Publications (1)

Publication Number Publication Date
DK3236972T3 true DK3236972T3 (en) 2021-10-04

Family

ID=56151433

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15874145.4T DK3236972T3 (en) 2014-12-26 2015-12-16 Antivirale N4-hydroxycytidin-derivativer

Country Status (23)

Country Link
US (3) US20190022116A1 (en)
EP (2) EP3236972B1 (en)
JP (4) JP7381190B2 (en)
KR (2) KR20230130175A (en)
CN (2) CN118286245A (en)
AU (3) AU2015370004B2 (en)
BR (1) BR112017013858A2 (en)
CA (1) CA2972259A1 (en)
CY (1) CY1124663T1 (en)
DK (1) DK3236972T3 (en)
EA (1) EA201791460A1 (en)
ES (1) ES2892123T3 (en)
HR (1) HRP20211456T1 (en)
HU (1) HUE056470T2 (en)
IL (3) IL296496B2 (en)
LT (1) LT3236972T (en)
PL (1) PL3236972T3 (en)
PT (1) PT3236972T (en)
RS (1) RS62434B1 (en)
SG (2) SG10202105371YA (en)
SI (1) SI3236972T1 (en)
SM (1) SMT202100592T1 (en)
WO (1) WO2016106050A1 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202105371YA (en) * 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11414659B2 (en) 2016-09-02 2022-08-16 Dicerna Pharmaceuticals, Inc. 4'-phosphate analogs and oligonucleotides comprising the same
JP7016170B2 (en) * 2016-12-16 2022-02-04 国立大学法人東海国立大学機構 Nucleoside derivatives and their uses
WO2019088179A1 (en) 2017-10-31 2019-05-09 ヤマサ醤油株式会社 Nucleoside derivative and use thereof
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
CA3082191C (en) 2017-12-07 2021-09-21 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN108586294A (en) * 2018-05-29 2018-09-28 王若锴 A kind of carbamide derivative and its application in preventing inflammation
KR102783030B1 (en) * 2019-02-01 2025-03-18 재단법인 경기도경제과학진흥원 Pharmaceutical composition for treating or preventing middle east respiratory syndrome
CN112390838A (en) * 2019-08-14 2021-02-23 斯微(上海)生物科技有限公司 Modified nucleoside and synthetic method thereof
PH12022550438A1 (en) * 2020-02-07 2022-12-19 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN111548384B (en) * 2020-03-29 2021-04-27 常州安蒂卫生物科技有限公司 Substituted N4-hydroxycytidine derivatives and prodrugs thereof for antiviral therapy
US20230255957A1 (en) * 2020-04-03 2023-08-17 Selva Therapeutics, Inc. Viral entry inhibitors and rna polymerase inhibitors
US11826382B2 (en) 2020-05-01 2023-11-28 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US12042514B2 (en) 2020-05-01 2024-07-23 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US11642372B2 (en) 2020-05-01 2023-05-09 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
WO2022020793A1 (en) * 2020-07-24 2022-01-27 The Regents Of The University Of California Antiviral prodrugs, pharmaceutical formulations, and methods
US11702440B2 (en) * 2020-12-10 2023-07-18 Optimus Drugs Private Limited Pharmaceutical polymorphs of Molnupiravir
CN114621229B (en) * 2020-12-11 2024-07-02 嘉兴金派特生物科技有限公司 Compounds or compositions for treating or preventing infectious peritonitis in cats
CN112279877B (en) * 2020-12-15 2021-08-06 南京颐媛生物医学研究院有限公司 Nucleoside phosphate and synthesis method thereof
CA3201732A1 (en) * 2020-12-18 2022-06-23 Tamas BENKOVICS Synthesis of antiviral nucleosides
CN112608357B (en) * 2020-12-21 2022-12-09 杭州科巢生物科技有限公司 Preparation method of antiviral drug Molnbupiravir
CN112939981B (en) * 2021-01-19 2022-08-26 嘉兴金派特生物科技有限公司 Nucleoside compound, pharmaceutically acceptable salt, composition and application thereof
US20240100018A1 (en) * 2021-01-22 2024-03-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compounds for the treatment of a disease or disorder, methods for identifying said compounds
EP4319763A4 (en) * 2021-04-09 2025-06-11 Emory University Modified nucleosides and nucleotides analogs as antiviral agents for corona and other viruses
US11407779B1 (en) * 2021-04-23 2022-08-09 Divi's Laboratories Ltd. Process for the preparation of molnupiravir
WO2022234598A1 (en) * 2021-05-06 2022-11-10 Council Of Scientific And Industrial Research A process for the preparation of n4-hydroxycytidine and its derivatives
WO2022251663A2 (en) * 2021-05-27 2022-12-01 Emory University Novel universal anti-rna virus agents
CN117642410A (en) * 2021-06-18 2024-03-01 苏州春海生物医药有限公司 Ester derivatives of N4-hydroxycytidine and uses thereof
CN113321694A (en) * 2021-06-22 2021-08-31 药康众拓(江苏)医药科技有限公司 N4-hydroxycytidine derivative and preparation method and application thereof
CN113735929A (en) * 2021-07-21 2021-12-03 海化生命(厦门)科技有限公司 Anti-coronavirus compound and preparation method and application thereof
CA3226836A1 (en) 2021-08-06 2023-02-09 Intervet International B.V. Method of treating veterinary viral diseases
CN115960148B (en) * 2021-08-27 2023-12-12 南京知和医药科技有限公司 Novel cytidine derivative, and pharmaceutical composition and application thereof
CN113980074A (en) * 2021-10-21 2022-01-28 苏州立新制药有限公司 Crystal form A of N4-hydroxycytidine, preparation method and application
TW202333706A (en) 2021-11-01 2023-09-01 德商埃慕尼克股份公司 Medical use of n-hydroxy citicoline compounds
AU2022387700A1 (en) * 2021-11-12 2024-05-30 Suzhou Spring-Sea Bio-Pharmaceuticals Co., Ltd. Ester derivatives of n4-hydroxycytidine and use thereof
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN116496334A (en) * 2022-01-25 2023-07-28 上海和誉生物医药科技有限公司 A kind of antiviral inhibitor and its application in medicine
CN116554249B (en) * 2022-01-28 2025-03-18 北京恩泰伟医药科技有限公司 Antiviral compounds and uses thereof
TW202348228A (en) 2022-02-24 2023-12-16 德商艾斯巴赫生物有限公司 Viral combination therapy
WO2023167488A1 (en) * 2022-03-02 2023-09-07 유재혁 Veterinary composition for topical administration of molnupiravir and use thereof
CN116731087A (en) * 2022-03-03 2023-09-12 上海科胜药物研发有限公司 Preparation method of monabivalir and intermediate thereof
KR20230130898A (en) * 2022-03-04 2023-09-12 동아대학교 산학협력단 N4-o-isobutyryloxycytidine analogs and anti-viral uses thereof
CN114573651A (en) * 2022-03-11 2022-06-03 山东大学 N4-hydroxycytidine lipid prodrug and preparation method and application thereof
CN119546620A (en) 2022-03-15 2025-02-28 罗梅治疗股份有限公司 Compounds and methods for treating disease
CN114805458B (en) * 2022-03-31 2023-09-08 中国人民解放军军事科学院军事医学研究院 Fatty acid prodrug of nucleoside broad-spectrum antiviral drug, preparation method and application thereof
WO2024123206A1 (en) * 2022-12-08 2024-06-13 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Method for producing 5'-о-(3-phenylpropionyl)-n4-hydroxycytidine
WO2024123207A1 (en) * 2022-12-08 2024-06-13 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации 5'-о-(3-phenylpropionyl)-n4-hydroxycytidine and use thereof

Family Cites Families (280)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1325798A (en) 1970-09-24 1973-08-08 Upjohn Co Derivatives of 2,2-anhydro-ara-cytidine
GB1386334A (en) 1972-09-22 1975-03-05 Kohjin Co 2,2-cyclocytidine derivatives
GB1480120A (en) 1973-11-29 1977-07-20 Kohjin Co N4-substituted-2,2'-cyclocytidine derivatives
US4096324A (en) 1975-07-07 1978-06-20 The Upjohn Company Cytidine nucleoside compound
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
JPH05500799A (en) 1989-06-05 1993-02-18 ギリアド　サイエンシス，インコーポレイテッド Exonuclease-resistant oligonucleotide and method for its preparation
WO1992009705A1 (en) 1990-11-23 1992-06-11 Gilead Sciences, Inc. Triplex-forming oligomers containing modified bases
RU2085557C1 (en) * 1991-09-30 1997-07-27 Санкио Компани Лимитед Pyrimidine nucleoside derivatives or their pharmaceutically acceptable salts and method of their synthesis
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
IS2334B (en) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
EP0695306A1 (en) 1993-04-19 1996-02-07 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5349947A (en) * 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
CA2171743C (en) 1993-09-17 2007-11-20 Norbert W. Bischofberger Nucleotide analogs
AU690587B2 (en) 1993-09-17 1998-04-30 Gilead Sciences, Inc. Method for dosing therapeutic compounds
MX9706496A (en) 1995-02-27 1997-11-29 Gilead Sciences Inc Novel selective inhibitors of viral or bacterial neuraminidases.
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
EP0938475A1 (en) 1996-10-21 1999-09-01 Gilead Sciences, Inc. Piperidine compounds
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
NZ547204A (en) 2000-05-26 2008-01-31 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP2251015B1 (en) 2000-10-18 2013-02-20 Gilead Pharmasset LLC Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
CA2743451A1 (en) 2000-10-18 2002-04-25 Pharmasset, Inc. Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
AU2002228885A1 (en) 2000-10-18 2002-04-29 Pharmasset Inc Simultaneous quantification of nucleic acids in diseased cells
HUP0400732A3 (en) 2001-04-30 2007-05-29 Trommsdorff Arzneimittel Pharmaceutically active uridine esters
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US7049303B2 (en) 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
CN101074242A (en) 2002-04-26 2007-11-21 吉里德科学公司 Cells accumulation for sphosphonate analogs of HIV protease inhibitor compound and the same compound
US20050239054A1 (en) 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
JP4806187B2 (en) 2002-07-15 2011-11-02 ギリード・サイエンシズ・インコーポレーテッド Combination therapy with L-FMAU for the treatment of hepatitis B virus
AU2003264406A1 (en) 2002-09-11 2004-04-30 Michio Ishibashi Drug or cosmetic
MXPA05003434A (en) 2002-10-01 2005-07-05 Gilead Sciences Inc Hbv mutations associated with reduced susceptibility to adefovir.
US20040157804A1 (en) 2002-10-16 2004-08-12 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
AU2003287606A1 (en) * 2002-11-12 2004-06-03 Enzon Pharmaceuticals, Inc. Novel acylating reagents
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
AU2003297612A1 (en) 2002-12-02 2004-06-23 Gilead Sciences, Inc. 2-substituted-3-propenamide derivatives and methods of using the same
ATE398455T1 (en) 2003-01-14 2008-07-15 Gilead Sciences Inc COMPOSITIONS AND METHODS FOR ANTIVIRAL COMBINATION THERAPY
WO2004100960A2 (en) 2003-04-25 2004-11-25 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
PT1628685E (en) 2003-04-25 2011-03-16 Gilead Sciences Inc Antiviral phosphonate analogs
CN101410120A (en) 2003-04-25 2009-04-15 吉里德科学公司 Anti-inflammatory phosphonate compounds
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
AU2004260789B2 (en) 2003-07-30 2011-06-30 Gilead Sciences, Inc. Nucleobase phosphonate analogs for antiviral treatment
US7462721B2 (en) 2003-09-19 2008-12-09 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
RU2264409C2 (en) * 2003-10-01 2005-11-20 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") 2'-amino-2'-deoxynucleosides as inhibitors if measles and marburg virusus reproduction
CA2543144A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
US20070160554A1 (en) 2003-11-03 2007-07-12 Cognis Ip Management Gmbh Acyl ribonucleosides and acyl deoxyribonucleosides, compositions of, and methods of making same
KR20060127906A (en) 2003-12-22 2006-12-13 길리애드 사이언시즈, 인코포레이티드 4'-substituted carver and avacavir derivatives and related compounds having HIV and HCV antiviral activity
EP2161273B1 (en) 2003-12-22 2015-04-15 K.U.Leuven Research & Development Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
WO2005066189A1 (en) 2003-12-30 2005-07-21 Gilead Sciences, Inc. Phosphonates, monophosphonamidates, bisphosphonamidates for the treatment of viral diseases
MXPA06007906A (en) 2004-01-12 2007-02-14 Gilead Sciences Inc Pyrimidyl phosphonate antiviral compounds and methods of use.
WO2005072748A1 (en) 2004-01-21 2005-08-11 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting mmtv-like viruses involved in breast cancer and primary biliary cirrhosis
DK1742642T3 (en) 2004-04-14 2009-02-16 Gilead Sciences Inc Phosphonate analogues of HIV integrase inhibitor compounds
UA93354C2 (en) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Topical antiviral formulations
WO2006020276A2 (en) 2004-07-16 2006-02-23 Gilead Sciences, Inc. Antiviral compounds
HRP20070078A2 (en) 2004-07-27 2007-05-31 Gilead Sciences PHOSPHONATE ANALYSIS OF HIV INHIBITING COMPOUNDS
MX2007001054A (en) 2004-07-27 2007-07-25 Gilead Sciences Inc Imidazo[4,5-d]pyrimidines, their uses and methods of preparation.
DE102004051804A1 (en) * 2004-10-21 2006-04-27 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Beta-L-N4-hydroxycytosine deoxynucleosides and their use as pharmaceutical agents for the prophylaxis or therapy of viral diseases
US20080171724A1 (en) 2004-10-26 2008-07-17 Gilead Sciences, Inc. Phosphonate Derivatives of Mycophenolic Acid
ATE426601T1 (en) 2004-12-21 2009-04-15 Gilead Sciences Inc IMIDAZOA4,5-CUPYRIDINE COMPOUND AND METHOD FOR ANTIVIRAL TREATMENT
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
EP1888581A2 (en) 2005-05-16 2008-02-20 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
JP5461009B2 (en) 2005-06-08 2014-04-02 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Method for promoting neuronal cell survival using non-peptide and peptide BDNF neurotrophin analogues
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI389908B (en) 2005-07-14 2013-03-21 Gilead Sciences Inc Antiviral compounds
WO2007014174A2 (en) 2005-07-25 2007-02-01 Gilead Sciences, Inc. Drug-resistant mutants of hepatitis c virus
CA2616314A1 (en) 2005-07-27 2007-02-01 Gilead Sciences, Inc. Antiviral phosphonate conjugates for inhibition of hiv
EP1919924A2 (en) 2005-08-16 2008-05-14 Irm, Llc Compounds and compositions as protein kinase inhibitors
WO2007039413A2 (en) 2005-09-22 2007-04-12 F. Hoffmann-La Roche Ag Selective o-acylation of nucleosides
EA018544B1 (en) 2005-12-30 2013-08-30 Джилид Сайэнс, Инк. Method for treating retroviral infection
HRP20140626A2 (en) 2006-03-29 2014-11-07 Gilead Sciences, Inc. Process for preparation of hiv protease inhibitors
US20090318456A1 (en) 2006-07-06 2009-12-24 Gilead Sciences, Inc. Substituted pteridines for the treatment and prevention of viral infections
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
EA020489B1 (en) 2006-07-07 2014-11-28 Джилид Сайэнс, Инк. Modulators of pharmacokinetic properties of therapeutics
AU2007269557B2 (en) 2006-07-07 2013-11-07 Gilead Sciences, Inc. Modulators of toll-like receptor 7
AU2007269614B2 (en) 2006-07-07 2011-09-08 Gilead Sciences, Inc. Novel pyridazine compound and use thereof
WO2008009079A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
WO2008009077A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
EP2049547A2 (en) 2006-07-21 2009-04-22 Gilead Sciences, Inc. Aza-peptide protease inhibitors
EP2069303B1 (en) 2006-07-21 2016-03-30 Gilead Sciences, Inc. Antiviral protease inhibitors
EP2069356A1 (en) 2006-07-24 2009-06-17 Gilead Sciences, Inc. Bisfuranyl protease inhibitors
KR20090040449A (en) 2006-07-24 2009-04-24 길리애드 사이언시즈, 인코포레이티드 New HIV Reverse Transcriptase Inhibitor
WO2008039538A2 (en) 2006-09-27 2008-04-03 Coley Pharmaceutical Group, Inc. Compositions of tlr ligands and antivirals
EP2094702B1 (en) 2006-12-14 2015-09-02 Gilead Sciences, Inc. Viral inhibitors
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
US8637531B2 (en) 2006-12-26 2014-01-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyridmidines useful for treating viral infections
WO2008077649A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infectons
US8324179B2 (en) 2007-02-09 2012-12-04 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
EA019893B1 (en) 2007-02-23 2014-07-30 Джилид Сайэнс, Инк. Pharmaceutical composition and method for treating hiv infection
JP2010522705A (en) 2007-03-29 2010-07-08 エフ．ホフマン−ラ ロシュ アーゲー Pharmaceutical composition and production method
TW200918524A (en) 2007-06-29 2009-05-01 Gilead Sciences Inc Antiviral compounds
US20090093467A1 (en) 2007-06-29 2009-04-09 Gilead Sciences, Inc. Therapeutic compositions and methods
SG182228A1 (en) 2007-06-29 2012-07-30 Gilead Sciences Inc Therapeutic compositions and uses thereof
US8513186B2 (en) 2007-06-29 2013-08-20 Gilead Sciences, Inc. Antiviral compounds
CN101790524B (en) 2007-06-29 2014-07-16 吉里德科学公司 Antiviral compounds
ES2533863T3 (en) 2007-06-29 2015-04-15 Korea Research Institute Of Chemical Technology Novel HIV reverse transcriptase inhibitors
KR20100041798A (en) 2007-06-29 2010-04-22 한국화학연구원 Novel hiv reverse transcriptase inhibitors
KR101561710B1 (en) 2007-06-29 2015-10-19 길리애드 사이언시즈, 인코포레이티드 Purine derivatives and their use as modulators of toll-like receptor 7
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
EP2205073A4 (en) * 2007-09-26 2013-03-06 Sinai School Medicine Azacytidine analogues and uses thereof
WO2009058800A2 (en) 2007-10-29 2009-05-07 President And Fellows Of Harvard College Synthesis of nucleosides
CA2710832A1 (en) * 2007-12-27 2009-07-09 Epiphany Biosciences, Inc. Antiviral compounds
EP2231628B1 (en) 2008-01-04 2015-10-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
TWI444384B (en) 2008-02-20 2014-07-11 Gilead Sciences Inc Nucleotide analogues and their use in the treatment of malignancies
WO2009132135A1 (en) 2008-04-23 2009-10-29 Gilead Sciences, Inc. 1' -substituted carba-nucleoside analogs for antiviral treatment
WO2009143011A1 (en) * 2008-05-20 2009-11-26 Novartis Ag Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
WO2010002998A1 (en) 2008-07-03 2010-01-07 Gilead Sciences, Inc. 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS
ES2393962T3 (en) 2008-07-08 2013-01-03 Gilead Sciences, Inc. Salts of HIV inhibitor compounds.
AU2009273844A1 (en) 2008-07-25 2010-01-28 Gilead Sciences, Inc. Antiviral compounds
CA2745295C (en) 2008-12-09 2017-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
TW201034663A (en) 2008-12-19 2010-10-01 Gilead Sciences Inc HCV NS3 protease inhibitors
JP2012513397A (en) 2008-12-22 2012-06-14 ギリアード サイエンシーズ， インコーポレイテッド Antiviral compounds
EP2719701B1 (en) 2009-02-10 2017-04-05 Gilead Sciences, Inc. Method for the preparation of thieno[3,4-d]pyrimidin-7-yl ribosides
BR122014012810B1 (en) 2009-05-13 2020-04-14 Gilead Pharmasset Llc pharmaceutical composition comprising a combination of antiviral compounds and use of said compounds for the preparation of said composition
TWI583692B (en) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 Nucleoside phosphoramidates
WO2010151472A1 (en) 2009-06-23 2010-12-29 Gilead Sciences, Inc. Combination of a ns5b polymerase inhibitor and a hcv ns3 protease inhibitor for the treatment of hcv
UY32720A (en) 2009-06-23 2011-01-31 Gilead Sciences Inc PHARMACEUTICAL COMBINATIONS USEFUL FOR THE TREATMENT OF HEPATITIS C (HCV) VIRUSES, USES AND RELATED METHODS
TW201113279A (en) 2009-06-23 2011-04-16 Gilead Sciences Inc Pharmaceutical compositions useful for treating HCV
WO2011005842A1 (en) 2009-07-09 2011-01-13 Gilead Sciences, Inc. Anti-rsv compounds
SG177709A1 (en) 2009-07-21 2012-02-28 Gilead Sciences Inc Inhibitors of flaviviridae viruses
CN102498118A (en) 2009-09-09 2012-06-13 吉里德科学公司 Inhibitors of flaviviridae viruses
AU2010292102B2 (en) 2009-09-14 2015-04-09 Gilead Sciences, Inc. Modulators of Toll-like receptors
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
BR122021012877B8 (en) 2009-09-21 2021-12-14 Gilead Sciences Inc Analogous compounds of substituted 2'-fluoro carbanucleoside, use thereof and pharmaceutical composition comprising them
SG10201406813RA (en) 2009-10-22 2014-11-27 Gilead Sciences Inc Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
JP5777223B2 (en) 2010-01-15 2015-09-09 ギリアード サイエンシーズ， インコーポレイテッド Inhibitors of Flaviviridae virus
PL2523950T3 (en) 2010-01-15 2017-09-29 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
BR112012015951A2 (en) 2010-01-28 2018-10-16 Hoffmann La Roche 4 azido nucleosides as anti-hcv compounds
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
JP2013523712A (en) * 2010-03-30 2013-06-17 クラヴィス・ファルマ・アーエスアー Methods and compositions for treating or alleviating cancer using gemcitabine-5'-elaidate
UY33373A (en) 2010-05-10 2011-12-30 Gilead Sciences Inc ? Bifunctional pyrazolopyridine compounds, their use in therapy and compositions that comprise them ?.
US8394829B2 (en) 2010-05-10 2013-03-12 Gilead Sciences, Inc. Bi-functional quinoline analogs
NZ603310A (en) 2010-05-21 2015-01-30 Gilead Sciences Inc Heterocyclic flaviviridae virus inhibitors
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
AR084393A1 (en) 2010-06-10 2013-05-15 Gilead Sciences Inc METHODS TO TREAT HEPATITIS C VIRUS, COMPOSITION, USE, COMBINATION, KIT AND ONE OR MORE ANTI HCV COMPOUNDS
ES2551738T3 (en) 2010-06-11 2015-11-23 Gilead Sciences, Inc. Topical antiviral formulations for the prevention of HSV-2 transmission
JP2013538182A (en) * 2010-06-16 2013-10-10 クラビス ファーマ エイエスエイ Anti-human balanced nucleoside transporter 1 (hENT1) antibody and method of using the same
EP3012258B1 (en) 2010-06-24 2018-09-19 Gilead Sciences, Inc. Pharmaceutical composition comprising a pyrazolo[1,5-a]pyrimidine derivative as an antiviral agent
CA2802492C (en) 2010-07-02 2018-10-16 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
PT2588450T (en) 2010-07-02 2017-08-03 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat aids
KR20200052384A (en) 2010-07-19 2020-05-14 길리애드 사이언시즈, 인코포레이티드 Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
ME01924B (en) 2010-07-22 2015-05-20 Gilead Sciences Inc Methods and compounds for treating Paramyxoviridae virus infections
CN102351931B (en) 2010-09-07 2014-01-22 河南省科学院高新技术研究中心 Pyrimidine nucleoside derivatives as well as synthesis method and application thereof in preparation of anti-tumor and antiviral drugs
TW201305185A (en) 2010-09-13 2013-02-01 Gilead Sciences Inc 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
CA2807496C (en) 2010-09-20 2019-01-22 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
KR20200140924A (en) 2010-11-17 2020-12-16 길리애드 파마셋 엘엘씨 Antiviral compounds
UA114075C2 (en) 2010-11-19 2017-04-25 MULTI-LAYER TABLE CONTAINING RILPIVIRINE HCl, EMTRICITABIN AND TENOFOVIR DISOPROXYLFUMARATE
AR084217A1 (en) 2010-12-10 2013-05-02 Gilead Sciences Inc MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE
NZ613370A (en) 2010-12-20 2015-05-29 Gilead Sciences Inc Combinations for treating hcv
US8987313B2 (en) 2010-12-21 2015-03-24 Gilead Sciences, Inc. Inhibitors of cytochrome P450
WO2012088178A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
WO2012088153A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
TW201302761A (en) 2011-04-04 2013-01-16 Gilead Sciences Inc Solid state forms of HIV inhibitor
EP2694479A1 (en) 2011-04-04 2014-02-12 Gilead Sciences, Inc. Process for the preparation of an hiv integrase inhibitor
KR20140019832A (en) 2011-04-13 2014-02-17 길리애드 사이언시즈, 인코포레이티드 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
KR20140027295A (en) 2011-04-21 2014-03-06 길리애드 사이언시즈, 인코포레이티드 Benzothiazole compounds and their pharmaceutical use
JP2014513123A (en) 2011-05-02 2014-05-29 ギリアード サイエンシーズ， インコーポレイテッド Amorphous solid salt
JP2014522648A (en) 2011-07-06 2014-09-08 ギリアード サイエンシーズ， インコーポレイテッド HCV genotype 3 replicon
WO2013006721A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Hcv genotype 4 replicons
EP2729448B1 (en) 2011-07-06 2015-09-09 Gilead Sciences, Inc. Compounds for the treatment of hiv
US8741946B2 (en) 2011-07-13 2014-06-03 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
PE20141328A1 (en) 2011-08-16 2014-10-04 Gilead Sciences Inc TENOFOVIR ALAFENAMIDE HEMIFUMARATE
ME03009B (en) * 2011-09-16 2018-10-20 Gilead Pharmasset Llc Methods for treating hcv
EP2776024A1 (en) 2011-10-31 2014-09-17 Gilead Pharmasset LLC Methods and compositions for treating hepatitis c virus
EP2635588B1 (en) 2011-11-16 2015-06-10 Gilead Pharmasset LLC Condensed imidazolylimidazoles as antiviral compounds
EP3777867A1 (en) 2011-11-29 2021-02-17 Gilead Pharmasset LLC Composition and methods for treating hepatitis c virus
WO2013090840A1 (en) 2011-12-15 2013-06-20 Gilead Sciences, Inc. 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors
WO2013090929A1 (en) 2011-12-15 2013-06-20 Gilead Sciences, Inc. Amino quinoline derivatives inhibitors of hcv
WO2013096512A1 (en) 2011-12-20 2013-06-27 Gilead Sciences, Inc. Pharmaceutical compositions and methods for treating gastrointestinal infections and disorders
WO2013096681A1 (en) 2011-12-22 2013-06-27 Gilead Sciences, Inc. Pyrazolo[1,5-a]pyrimidines as antiviral agents
CA3107640A1 (en) * 2011-12-22 2013-06-27 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof and their use in ameliorating or treating a disease or condition associated with viral infections
WO2013103724A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. 2- (tert - butoxy) -2- (7 -methylquinolin- 6 - yl) acetic acid derivatives for treating aids
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
AU2013207825A1 (en) 2012-01-12 2014-08-28 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
WO2013116720A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising tenofovir alafenamide hemifumarate and cobicistat for use in the treatment of viral infections
AU2012327170A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
EP3210993B1 (en) 2012-03-13 2018-12-12 Gilead Sciences, Inc. 2'- substituted carba-nucleoside analogs for antiviral treatment
PL2827875T3 (en) * 2012-03-21 2019-07-31 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2870024C (en) 2012-04-17 2020-04-07 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
UY34750A (en) 2012-04-20 2013-11-29 Gilead Sciences Inc ? COMPOUNDS FOR HIV TREATMENT, COMPOSITIONS, PREPARATION METHODS, INTERMEDIARIES AND THERAPEUTIC METHODS ?.
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
AR091279A1 (en) 2012-06-08 2015-01-21 Gilead Sciences Inc MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE
SI2859009T1 (en) 2012-06-08 2017-12-29 Gilead Sciences, Inc. Macrocyclic inhibitors of flaviviridae viruses
MX2014014766A (en) 2012-06-08 2015-05-11 Gilead Sciences Inc Macrocyclic inhibitors of flaviviridae viruses.
UA119315C2 (en) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі HEPATITIS VIRUS INHIBITORS C
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US20140094485A1 (en) 2012-10-03 2014-04-03 Gilead Sciences, Inc. Solid state forms of hiv inhibitor
BR112015008757A2 (en) 2012-10-26 2017-07-04 Koninklijke Philips Nv display device and method for operating a display device
JP2015535261A (en) * 2012-10-29 2015-12-10 コクリスタル ファーマ，インコーポレイテッド Pyrimidine nucleotides and their monophosphate prodrugs for the treatment of viral infections and cancer
KR20150074179A (en) 2012-10-30 2015-07-01 길리애드 사이언시즈, 인코포레이티드 Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
JP2015534821A (en) 2012-11-07 2015-12-07 ギリアード サイエンシーズ， インコーポレイテッド HCV genotype 6 replicon
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
MY164352A (en) 2012-12-21 2017-12-15 Gilead Sciences Inc Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
KR102788773B1 (en) 2012-12-21 2025-03-28 얀센 바이오파마, 인코퍼레이트. Substituted nucleosides, nucleotides and analogs thereof
TW201443037A (en) 2013-01-09 2014-11-16 Gilead Sciences Inc Therapeutic compounds
NZ727792A (en) 2013-01-09 2018-04-27 Gilead Sciences Inc Therapeutic compounds
JP5941598B2 (en) 2013-01-09 2016-06-29 ギリアード サイエンシーズ， インコーポレイテッド 5-membered heteroaryls and their use as antiviral agents
WO2014124430A1 (en) * 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
TWI706945B (en) 2013-03-01 2020-10-11 美商基利科學股份有限公司 Therapeutic compounds for treating a retroviridae viral infection
US20140273023A1 (en) * 2013-03-15 2014-09-18 Saladax Biomedical Inc. Gemcitabine immunoassay
WO2014145095A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis c virus
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
RU2015148006A (en) * 2013-04-12 2017-05-18 Ачиллион Фармасютикалз, Инк. DEUTERED NUCLEOSIDE MEDICINES APPLICABLE FOR HCV TREATMENT
MA38675A1 (en) 2013-05-16 2017-12-29 Riboscience Llc Derivatives of substituted 4'-fluoro-2'-methyl nucleosides useful for inhibiting the replication of hepatitis c (hcv)
CA2913206C (en) 2013-06-26 2022-08-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US20150072418A1 (en) 2013-08-16 2015-03-12 Gilead Sciences, Inc. Hcv genotype 4d replicons
PL3043803T3 (en) 2013-09-11 2022-11-07 Emory University Nucleotide and nucleoside compositions and their uses
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
UA119050C2 (en) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. PYROL [1.2-f] [1.2.4] TRIASINES USED FOR TREATMENT OF RESPIRATORY-SYNCITAL VIRAL INFECTIONS
US20150150897A1 (en) 2013-12-02 2015-06-04 Gilead Pharmasset Llc Methods of treating hepatitis c virus infection in subjects with cirrhosis
WO2015100144A1 (en) 2013-12-23 2015-07-02 Gilead Sciences, Inc. Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
TW201609785A (en) 2013-12-23 2016-03-16 吉李德製藥公司 Solid forms of an antiviral compound
TWI660965B (en) 2014-01-15 2019-06-01 美商基利科學股份有限公司 Solid forms of tenofovir
WO2015120057A1 (en) 2014-02-05 2015-08-13 Gilead Sciences, Inc. Pharmaceutical combinations against co-infection with hiv and tuberculosis
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015179448A1 (en) 2014-05-21 2015-11-26 Gilead Sciences, Inc. Therapeutic compounds
PT3154985T (en) 2014-06-12 2018-10-19 Gilead Sciences Inc Antiviral compounds
JP6383810B2 (en) 2014-06-13 2018-08-29 ギリアード サイエンシーズ， インコーポレイテッド Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
EA201692265A1 (en) 2014-06-13 2017-05-31 Джилид Сайэнс, Инк. PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
NZ726608A (en) 2014-06-13 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
JP6455995B2 (en) 2014-06-13 2019-01-23 ギリアード サイエンシーズ， インコーポレイテッド Phosphatidylinositol 3-kinase inhibitor
AU2015274628B2 (en) 2014-06-13 2018-03-15 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US9603864B2 (en) 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AP2016009653A0 (en) 2014-06-24 2016-12-31 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
CN105288635A (en) 2014-06-26 2016-02-03 昆明积大制药股份有限公司 Pharmaceutical composition containing 5'-Ara-C-O-amino ester
PL3166607T3 (en) 2014-07-11 2023-02-20 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
TWI678369B (en) 2014-07-28 2019-12-01 美商基利科學股份有限公司 Thieno[3,2-d]pyrimidine, furo[3,2-d]pyrimidine, and pyrrolo[3,2-d]pyrimidines useful for treating respiratory syncitial virus infections
TWI673283B (en) 2014-08-21 2019-10-01 美商基利科學股份有限公司 2'-chloro aminopyrimidinone and pyrimidine dione nucleosides
PT3186239T (en) 2014-08-29 2019-01-10 Gilead Sciences Inc Antiretroviral agents
WO2016036759A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
TWI695003B (en) 2014-12-23 2020-06-01 美商基利科學股份有限公司 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PT3237397T (en) 2014-12-24 2019-02-08 Gilead Sciences Inc Isoquinoline compounds for the treatment of hiv
TWI699355B (en) 2014-12-24 2020-07-21 美商基利科學股份有限公司 Quinazoline compounds
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
SG10202105371YA (en) * 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2016134054A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
CR20170395A (en) 2015-03-04 2017-11-07 Gilead Sciences Inc TOLL TYPE RECEIVER MODULATING COMPOUNDS
SI3466490T1 (en) 2015-04-02 2020-12-31 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
AU2016250099A1 (en) 2015-04-14 2017-10-12 Gilead Sciences, Inc. Methods of treating hepatitis B virus
JP2018515541A (en) 2015-05-15 2018-06-14 ギリアード サイエンシーズ， インコーポレイテッド Benzimidazole and imidazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
MA46677A (en) 2015-06-17 2019-09-11 Gilead Sciences Inc CO-CRYSTALS, SALTS AND SOLID FORMS OF TENOFOVIR ALAFENAMIDE
ES2786549T3 (en) 2015-06-30 2020-10-13 Gilead Sciences Inc Pharmaceutical formulations comprising tenofovir and emtricitabine
CA2921336A1 (en) 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
KR102630013B1 (en) 2015-08-06 2024-01-25 키메릭스 인크. Pyrrolopyrimidine nucleosides and analogues thereof useful as antiviral agents
CA2995004A1 (en) 2015-08-26 2017-03-02 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
WO2017040896A1 (en) 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040895A1 (en) 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
US20170071944A1 (en) 2015-09-15 2017-03-16 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
MA52371A (en) 2015-09-16 2021-09-22 Gilead Sciences Inc METHODS OF TREATING CORONAVIRIDAE INFECTIONS
HK1258276A1 (en) 2015-09-30 2019-11-08 Gilead Sciences, Inc. Compounds and combinations for the treatment of hiv
WO2017059224A2 (en) 2015-10-01 2017-04-06 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
CA2948021C (en) 2015-11-09 2024-06-18 Gilead Sciences, Inc. Pharmaceutical formulations of (2r,5s,13 ar)-8hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzy1)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1'2':4,5]pyrazino [2,1-b][1,3] oxazepine-10-carboxamide
MY186414A (en) 2015-12-15 2021-07-22 Gilead Sciences Inc Human immunodeficiency virus neutralizing antibodies
CA2951911A1 (en) 2015-12-17 2017-06-17 Gilead Sciences, Inc. Tank-binding kinase inhibitor compounds
US10874683B2 (en) * 2016-03-10 2020-12-29 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
US11963972B2 (en) 2016-03-23 2024-04-23 Emory University Antiviral agents and nucleoside analogs for treatment of Zika virus
DK3377637T3 (en) 2016-04-08 2020-05-18 Krystal Biotech Inc COMPOSITIONS FOR USE IN PROCEDURES FOR TREATMENT OF SKIN SCREWS, DISEASES AND DISEASES
WO2017184668A1 (en) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
BR102017010009A2 (en) 2016-05-27 2017-12-12 Gilead Sciences, Inc. COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION
JP6770098B2 (en) 2016-05-27 2020-10-14 ギリアード サイエンシーズ， インコーポレイテッド Methods for treating hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors
US20200179428A1 (en) 2016-06-20 2020-06-11 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2017223268A1 (en) 2016-06-22 2017-12-28 Yale University COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi)
CA3082191C (en) * 2017-12-07 2021-09-21 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
GB2611644B (en) 2018-03-07 2023-07-26 Univ Emory 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
PH12022550438A1 (en) * 2020-02-07 2022-12-19 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Also Published As

Publication number Publication date
EP3939985B1 (en) 2024-05-08
JP2018500354A (en) 2018-01-11
IL296496A (en) 2022-11-01
JP2023153865A (en) 2023-10-18
IL252997A0 (en) 2017-08-31
SMT202100592T1 (en) 2021-11-12
IL279663B (en) 2022-10-01
SI3236972T1 (en) 2021-12-31
US20190022116A1 (en) 2019-01-24
RS62434B1 (en) 2021-11-30
IL279663A (en) 2021-03-01
EP3236972B1 (en) 2021-07-28
CN118286245A (en) 2024-07-05
KR20170123308A (en) 2017-11-07
PT3236972T (en) 2021-09-24
AU2021203840A1 (en) 2021-07-08
AU2021203840B2 (en) 2023-08-24
EP3236972A1 (en) 2017-11-01
JP2025098020A (en) 2025-07-01
HRP20211456T1 (en) 2021-12-24
CY1124663T1 (en) 2022-07-22
SG11201705069YA (en) 2017-07-28
IL296496B2 (en) 2024-10-01
US20210060050A1 (en) 2021-03-04
BR112017013858A2 (en) 2018-02-27
AU2015370004A1 (en) 2017-07-13
US11628181B2 (en) 2023-04-18
CA2972259A1 (en) 2016-06-30
AU2023270335A1 (en) 2023-12-14
AU2021203840C1 (en) 2024-01-25
EP3236972A4 (en) 2019-01-23
IL279663B2 (en) 2023-02-01
EA201791460A1 (en) 2017-12-29
LT3236972T (en) 2021-11-10
KR20230130175A (en) 2023-09-11
AU2015370004B2 (en) 2021-03-11
SG10202105371YA (en) 2021-07-29
ES2892123T3 (en) 2022-02-02
HUE056470T2 (en) 2022-02-28
JP2022058363A (en) 2022-04-12
EP3939985A1 (en) 2022-01-19
WO2016106050A1 (en) 2016-06-30
IL296496B1 (en) 2024-06-01
US20230293566A1 (en) 2023-09-21
PL3236972T3 (en) 2022-03-07
IL252997B (en) 2021-01-31
CN107427529A (en) 2017-12-01
JP7381190B2 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
DK3237446T3 (en) Anti-PD-1-antistoffer
DK3236972T3 (en) Antivirale N4-hydroxycytidin-derivativer
DK3373003T3 (en) Urinteststrimmel
AU361515S (en) Dishrack
AU362944S (en) Lapboard
DK3191586T3 (en) Cellobiosephosphorylase
DK3178931T3 (en) Anti-orai1-antistof
DK3002465T3 (en) Hydrauliksystem
DK3194944T3 (en) Tomografiapparat
GB201401268D0 (en) TrackPack
DK3145380T3 (en) Toiletventilationssystem
DK3234061T3 (en) Nano-inhibitorer
AU5598P (en) Lanidaho Mandevilla sanderi
AU5585P (en) Lanutah Mandevilla sanderi
AU5593P (en) Lanmissouri Mandevilla sanderi
AU5594P (en) Lanoregon Mandevilla sanderi
AU5597P (en) Lancalifornia Mandevilla sanderi
AU5583P (en) Lanminnesota Mandevilla sanderi
AU5584P (en) Laniowa Mandevilla sanderi
AU5591P (en) Lanmontana Mandevilla sanderi
AU5596P (en) Lannevada Mandevilla sanderi
AU5288P (en) FLOMANTOG Mandevilla sanderi
AU5289P (en) FLOMANFOP Mandevilla sanderi
AU5287P (en) FLOMANPIW Mandevilla sanderi
AU5286P (en) FLOMANWHW Mandevilla sanderi